Pharma News

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Vimpat® Tablets).

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has posed unprecedented challenges worldwide. While extensive efforts have focused on understanding the clinical features, diagnosis and treatment of COVID-19, certain aspects of the virus behavior, such as reactivation and recurrence, remain elusive. 

Enamel, the hardest and most mineral-rich substance in the human body, covers and protects our teeth. But in one of every 10 people – and in one third of children with celiac disease – this layer appears defective, failing to protect the teeth properly. As a result, teeth become more sensitive to heat, cold and sour food, and they may decay faster. In most cases, the cause of the faulty enamel production is unknown.

A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrial fibrillation (or AFib) an irregular, fast heartbeat that is associated with stroke and heart failure. The model picks up on tiny variations in a person’s normal heartbeat that signify AFib risk, which standard screening tests cannot detect.

The trial, by the University of Leeds, has been identified as groundbreaking research by the New England Journal of Medicine and the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, where the results have been presented.

Torrent Pharma has announced that the United States Food and Drug Administration (USFDA) has conducted the inspection with 5 procedural observations at the Company's Oral-Oncology manufacturing facility situated in Bileshwarpura, Gujarat.

AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc , a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform.

The ketogenic diet proved to be effective at controlling polycystic kidney disease (PKD) in the first randomized controlled clinical trial of ketogenic metabolic therapy for PKD.

The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy.